After co‐loading with DOX and siTGF‐β via electroporation, the generated Ds@ACTE efficiently reprogrammed the immunosuppressive microenvironment of GBM by downregulating anti‐inflammatory TGF‐β expression, which thus re‐sensitized the chemotherapeutic effect of DOX as well as boosted DOX‐initiated immune response, resulting in a synergistic therapeutic effect. This evidence concerns the gene TGFB1 and glioblastoma.